AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports
Tweet
Share
E-mail
A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble
(Reuters) -AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.
The agreement with Algen gives AstraZeneca exclusive rights to develop and commercialise therapies from the Crispr gene-editing technology, the report said.
Reuters could not immediately confirm the FT report.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Rashmi Aich)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Roche obesity drug shows 15.5% weight loss in diabetes trial
- Fed’s Williams defends current monetary policy framework
- Activist Corvex seeks Whitbread board seat over strategy concerns
Create E-mail Alert Related Categories
General News, ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
